NRX Pharmaceuticals, Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
NRX Pharmaceuticals, Inc. (NRXP) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $242.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-14.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2024-05-14
- NRX Pharmaceuticals, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2024-03-31 was $242.00K, a 65.18% decline year-over-year.
- NRX Pharmaceuticals, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2023-09-30 was $351.00K, a 35.12% decline year-over-year.
- NRX Pharmaceuticals, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2023-06-30 was $544.00K, a 44.88% decline year-over-year.
- NRX Pharmaceuticals, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2023-03-31 was $695.00K, a 47.90% decline year-over-year.
- NRX Pharmaceuticals, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $3.63M, a 18.29% decline from fiscal 2021.
- NRX Pharmaceuticals, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2021 was $4.44M, a 508.22% increase from fiscal 2020.
- NRX Pharmaceuticals, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2020 was $730.00K.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2024-03-31 | $242.00K 10-Q · filed 2024-05-14 | ||||
| 2023-09-30 | $351.00K 10-Q · filed 2023-11-14 | $895.00K derived: sum of 2 quarters · filed 2023-11-14 | $1.59M derived: sum of 3 quarters · filed 2024-05-14 | ||
| 2023-06-30 | $544.00K 10-Q · filed 2023-11-14 | $1.24M derived: sum of 2 quarters · filed 2024-05-14 | |||
| 2023-03-31 | $695.00K 10-Q · filed 2024-05-14 | ||||
| 2022-12-31 | $3.63M 10-K · filed 2023-03-31 | ||||
| 2022-09-30 | $541.00K 10-Q · filed 2023-11-14 | $1.53M derived: sum of 2 quarters · filed 2023-11-14 | $2.86M derived: sum of 3 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $987.00K 10-Q · filed 2023-11-14 | $2.32M derived: sum of 2 quarters · filed 2023-11-14 | |||
| 2022-03-31 | $1.33M 10-Q · filed 2023-11-14 | ||||
| 2021-12-31 | $4.44M 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $1.56M 10-Q · filed 2022-11-14 | $1.56M 10-Q · filed 2021-11-15 | $2.50M derived: sum of 2 quarters · filed 2022-11-14 | $2.87M derived: sum of 3 quarters · filed 2022-11-14 | |
| 2021-06-30 | $938.00K 10-Q · filed 2022-11-14 | $938.12K 10-Q · filed 2021-08-16 | $1.31M derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2021-03-31 | $372.00K 10-Q · filed 2022-11-14 | $371.70K 10-Q · filed 2021-08-16 | |||
| 2020-12-31 | $730.00K 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | $190.75K 10-Q/A · filed 2022-08-12 | $284.21K derived: sum of 2 quarters · filed 2022-08-12 | $373.02K derived: sum of 3 quarters · filed 2022-08-12 | ||
| 2020-06-30 | $93.47K 10-Q/A · filed 2022-08-12 | $182.27K derived: sum of 2 quarters · filed 2022-08-12 | |||
| 2020-03-31 | $88.80K 10-Q/A · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |